Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/bcr2604.

Title:
Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy | Breast Cancer Research
Description:
Introduction Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Methods Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Results Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. Conclusions This is the fifth independent study providing evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

breast, mammostrat, cancer, risk, status, cases, erpositive, patients, score, cancers, article, table, analysis, therapy, adjuvant, drfs, figure, tamoxifen, rfs, survival, google, scholar, data, treated, nodenegative, ernegative, clinical, nodal, pubmed, size, analyses, independent, outcome, study, prognostic, chemotherapy, results, tamoxifentreated, group, significant, recurrence, additional, receptor, file, treatment, distant, high, markers, univariate, lines,

Topics {✒️}

tamoxifen-resistant mcf-7 cells hormone-receptor-positive breast cancer early-stage breast cancer article download pdf conventional tnm staging node-negative breast cancer distant recurrence-free survival compare relapse-free survival er-expressing breast cancer tamoxifen-treated breast cancer breast-conserving surgery cases slightly larger er-positive low-risk breast cancers er-negative breast cancers er-positive breast cancers literature-based meta-analysis tamoxifen-treated breast cancers high-risk group exhibited multivariate regression analysis invasive tumor cells er-negative breast tumors er-negative population versus breast-conservation surgery mammostrat® high-risk group early breast cancer node-negative tumors treated john ms bartlett edinburgh cancer centre node-negative patients treated low-risk population treated er-positive tumors treated node-negative cases treated full size image breast-conserving surgery er-negative cases showed positive breast cancer large conservation series early breast cancers breast cancer specific breakthrough breast cancer tamoxifen-treated cases irrespective breast cancer res full access whilst er-negative cases recurrence-free survival privacy choices/manage cookies primary breast cancer kaplan-meier breast-conserving therapy relapse-free survival

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
         description:Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P &lt; 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P &lt; 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. This is the fifth independent study providing evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer.
         datePublished:2010-07-08T00:00:00Z
         dateModified:2010-07-08T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr2604
         keywords:
            Breast Cancer
            Overall Survival
            Tamoxifen
            Risk Score
            Nodal Status
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig2_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:John MS Bartlett
               affiliation:
                     name:Edinburgh Cancer Research Centre, Edinburgh University
                     address:
                        name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
                     name:Western General Hospital
                     address:
                        name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jeremy Thomas
               affiliation:
                     name:Western General Hospital
                     address:
                        name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas T Ross
               affiliation:
                     name:Clarient Inc.
                     address:
                        name:Clarient Inc., Aliso Viejo, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert S Seitz
               affiliation:
                     name:Clarient Inc.
                     address:
                        name:Clarient Inc., Aliso Viejo, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brian Z Ring
               affiliation:
                     name:Clarient Inc.
                     address:
                        name:Clarient Inc., Aliso Viejo, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rodney A Beck
               affiliation:
                     name:Clarient Inc.
                     address:
                        name:Clarient Inc., Aliso Viejo, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hans Christian Pedersen
               affiliation:
                     name:Edinburgh Cancer Research Centre, Edinburgh University
                     address:
                        name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alison Munro
               affiliation:
                     name:Edinburgh Cancer Research Centre, Edinburgh University
                     address:
                        name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ian H Kunkler
               affiliation:
                     name:Western General Hospital
                     address:
                        name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fiona M Campbell
               affiliation:
                     name:Edinburgh Cancer Research Centre, Edinburgh University
                     address:
                        name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wilma Jack
               affiliation:
                     name:Western General Hospital
                     address:
                        name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gillian R Kerr
               affiliation:
                     name:Western General Hospital
                     address:
                        name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Laura Johnstone
               affiliation:
                     name:Edinburgh Cancer Research Centre, Edinburgh University
                     address:
                        name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David A Cameron
               affiliation:
                     name:Western General Hospital
                     address:
                        name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Udi Chetty
               affiliation:
                     name:Western General Hospital
                     address:
                        name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
      description:Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up. Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm2 tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score. Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P &lt; 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P &lt; 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients. This is the fifth independent study providing evidence that Mammostrat® can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer.
      datePublished:2010-07-08T00:00:00Z
      dateModified:2010-07-08T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr2604
      keywords:
         Breast Cancer
         Overall Survival
         Tamoxifen
         Risk Score
         Nodal Status
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2604/MediaObjects/13058_2010_2565_Fig2_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:John MS Bartlett
            affiliation:
                  name:Edinburgh Cancer Research Centre, Edinburgh University
                  address:
                     name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
                  name:Western General Hospital
                  address:
                     name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jeremy Thomas
            affiliation:
                  name:Western General Hospital
                  address:
                     name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas T Ross
            affiliation:
                  name:Clarient Inc.
                  address:
                     name:Clarient Inc., Aliso Viejo, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert S Seitz
            affiliation:
                  name:Clarient Inc.
                  address:
                     name:Clarient Inc., Aliso Viejo, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brian Z Ring
            affiliation:
                  name:Clarient Inc.
                  address:
                     name:Clarient Inc., Aliso Viejo, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rodney A Beck
            affiliation:
                  name:Clarient Inc.
                  address:
                     name:Clarient Inc., Aliso Viejo, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hans Christian Pedersen
            affiliation:
                  name:Edinburgh Cancer Research Centre, Edinburgh University
                  address:
                     name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alison Munro
            affiliation:
                  name:Edinburgh Cancer Research Centre, Edinburgh University
                  address:
                     name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ian H Kunkler
            affiliation:
                  name:Western General Hospital
                  address:
                     name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fiona M Campbell
            affiliation:
                  name:Edinburgh Cancer Research Centre, Edinburgh University
                  address:
                     name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wilma Jack
            affiliation:
                  name:Western General Hospital
                  address:
                     name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gillian R Kerr
            affiliation:
                  name:Western General Hospital
                  address:
                     name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Laura Johnstone
            affiliation:
                  name:Edinburgh Cancer Research Centre, Edinburgh University
                  address:
                     name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David A Cameron
            affiliation:
                  name:Western General Hospital
                  address:
                     name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Udi Chetty
            affiliation:
                  name:Western General Hospital
                  address:
                     name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Edinburgh Cancer Research Centre, Edinburgh University
      address:
         name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
         type:PostalAddress
      name:Western General Hospital
      address:
         name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
         type:PostalAddress
      name:Western General Hospital
      address:
         name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
         type:PostalAddress
      name:Clarient Inc.
      address:
         name:Clarient Inc., Aliso Viejo, USA
         type:PostalAddress
      name:Clarient Inc.
      address:
         name:Clarient Inc., Aliso Viejo, USA
         type:PostalAddress
      name:Clarient Inc.
      address:
         name:Clarient Inc., Aliso Viejo, USA
         type:PostalAddress
      name:Clarient Inc.
      address:
         name:Clarient Inc., Aliso Viejo, USA
         type:PostalAddress
      name:Edinburgh Cancer Research Centre, Edinburgh University
      address:
         name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
         type:PostalAddress
      name:Edinburgh Cancer Research Centre, Edinburgh University
      address:
         name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
         type:PostalAddress
      name:Western General Hospital
      address:
         name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
         type:PostalAddress
      name:Edinburgh Cancer Research Centre, Edinburgh University
      address:
         name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
         type:PostalAddress
      name:Western General Hospital
      address:
         name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
         type:PostalAddress
      name:Western General Hospital
      address:
         name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
         type:PostalAddress
      name:Edinburgh Cancer Research Centre, Edinburgh University
      address:
         name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
         type:PostalAddress
      name:Western General Hospital
      address:
         name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
         type:PostalAddress
      name:Western General Hospital
      address:
         name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:John MS Bartlett
      affiliation:
            name:Edinburgh Cancer Research Centre, Edinburgh University
            address:
               name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
               type:PostalAddress
            type:Organization
            name:Western General Hospital
            address:
               name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jeremy Thomas
      affiliation:
            name:Western General Hospital
            address:
               name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Douglas T Ross
      affiliation:
            name:Clarient Inc.
            address:
               name:Clarient Inc., Aliso Viejo, USA
               type:PostalAddress
            type:Organization
      name:Robert S Seitz
      affiliation:
            name:Clarient Inc.
            address:
               name:Clarient Inc., Aliso Viejo, USA
               type:PostalAddress
            type:Organization
      name:Brian Z Ring
      affiliation:
            name:Clarient Inc.
            address:
               name:Clarient Inc., Aliso Viejo, USA
               type:PostalAddress
            type:Organization
      name:Rodney A Beck
      affiliation:
            name:Clarient Inc.
            address:
               name:Clarient Inc., Aliso Viejo, USA
               type:PostalAddress
            type:Organization
      name:Hans Christian Pedersen
      affiliation:
            name:Edinburgh Cancer Research Centre, Edinburgh University
            address:
               name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Alison Munro
      affiliation:
            name:Edinburgh Cancer Research Centre, Edinburgh University
            address:
               name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Ian H Kunkler
      affiliation:
            name:Western General Hospital
            address:
               name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Fiona M Campbell
      affiliation:
            name:Edinburgh Cancer Research Centre, Edinburgh University
            address:
               name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Wilma Jack
      affiliation:
            name:Western General Hospital
            address:
               name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Gillian R Kerr
      affiliation:
            name:Western General Hospital
            address:
               name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Laura Johnstone
      affiliation:
            name:Edinburgh Cancer Research Centre, Edinburgh University
            address:
               name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:David A Cameron
      affiliation:
            name:Western General Hospital
            address:
               name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
               type:PostalAddress
            type:Organization
      name:Udi Chetty
      affiliation:
            name:Western General Hospital
            address:
               name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
      name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
      name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
      name:Clarient Inc., Aliso Viejo, USA
      name:Clarient Inc., Aliso Viejo, USA
      name:Clarient Inc., Aliso Viejo, USA
      name:Clarient Inc., Aliso Viejo, USA
      name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
      name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
      name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
      name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
      name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
      name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
      name:Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Edinburgh, UK
      name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
      name:Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK

External Links {🔗}(116)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.21s.